My grandfather had gout. I know this because my dad mentions it occasionally, usually when reaching for a second glass of red wine. "Pop had gout," he'll say. "Had to give up the port. And the prawns."

In my dad's mental model, gout is something that happens to old men who drink port and eat too much shellfish. The "disease of kings," the swollen big toe, the rich-man's affliction. Something antiquated and self-inflicted and, honestly, a bit funny.

It's not funny. And it's not what most people think it is.

When my dad's most recent blood work came back, his uric acid was 0.41 mmol/L, with the upper limit at 0.42 for men. Not clinically elevated. But hovering at the boundary in a man whose father had gout, whose HbA1c has been borderline, whose cholesterol required a statin, and whose waist circumference has been tracked by his GP for three years.

His GP flagged it as something to monitor. Research over the past two decades has positioned hyperuricaemia (elevated uric acid) as an independent predictor of cardiovascular disease, chronic kidney disease, hypertension, metabolic syndrome, and all-cause mortality. The clinical relevance of uric acid extends far beyond whether your big toe swells up after Christmas dinner.

And yet, outside of people who've already had a gout attack, almost nobody gets their uric acid checked. It's not part of routine screening. It's not included in standard metabolic panels. It lives in a clinical blind spot.

This article covers what uric acid is, what gout actually involves, why uric acid matters as a metabolic marker independent of gout, and why Australians in particular should be paying attention.

A note before we get into it

What uric acid actually is, and why it matters beyond gout

Uric acid is the end product of purine metabolism. Purines are compounds found in your body's cells (released when cells break down as part of normal turnover) and in certain foods: red meat, organ meats, seafood, beer, and fructose-sweetened drinks.

Your body produces uric acid continuously. Under normal circumstances, it's filtered by the kidneys and excreted in urine, maintaining a stable blood level. The problems start when uric acid is produced faster than it's excreted, or when the kidneys become less efficient at clearing it. The blood level rises, and that's when things get complicated.

For decades, uric acid was treated as clinically irrelevant unless it caused gout. If you didn't have a swollen joint, your uric acid didn't matter. That view has changed substantially. Research now shows that elevated uric acid, even without gout, is associated with increased risk of hypertension, coronary artery disease, heart failure, atrial fibrillation, stroke, chronic kidney disease, metabolic syndrome, type 2 diabetes, and all-cause mortality.

Whether uric acid is a causal driver of these conditions or an innocent bystander (a marker of metabolic dysfunction rather than a cause of it) is still debated. The evidence is strongest for a causal role in hypertension and kidney disease, where uric acid appears to directly damage blood vessel endothelium and promote inflammation. For cardiovascular disease more broadly, the association is robust, but causation is harder to prove because hyperuricaemia clusters tightly with other metabolic risk factors.

What's not debated: uric acid provides clinically useful metabolic information. If it's elevated, something in your metabolic environment is off, whether that's dietary purine load, insulin resistance, kidney function, alcohol intake, fructose consumption, or medication effects. It's a signal worth reading.

Gout: not what you think it is

Let's dismantle the stereotype, because it matters for how seriously people take this condition.

What a gout attack feels like

Gout is the most common form of inflammatory arthritis. An acute gout attack occurs when monosodium urate crystals (tiny, needle-shaped crystals that form when uric acid levels are high enough for long enough) deposit in a joint and trigger an intense inflammatory response.

The classic presentation is the first metatarsophalangeal joint, the base of the big toe. But gout can affect the ankle, knee, wrist, fingers, and elbow. The onset is typically sudden, often overnight, and the pain is described as one of the most intense forms of joint pain in medicine. The affected joint becomes red, hot, swollen, and exquisitely tender, sometimes to the point where the weight of a bedsheet is unbearable.

Attacks typically resolve within 7 to 14 days, even without treatment. But untreated, they recur with increasing frequency and severity over time. And between attacks, the crystals remain in the joint, silently causing damage.

Who gets gout, and why the stereotype is wrong

Gout is not a disease of wealthy Edwardian gentlemen drinking port by the fire. In Australia, it affects approximately 5.2% of the adult population, roughly 8.5% of men and 2.1% of women. Hyperuricaemia (elevated uric acid without gout) affects between 10.5% and 16.6% of the Australian population.

Australia has one of the highest gout prevalences globally. The Australasian region, alongside North America, carries the greatest gout burden worldwide, a trend that has been increasing for decades and is projected to continue.

Risk factors include male sex (pre-menopausal women are partially protected by oestrogen's uricosuric effect), increasing age, family history, obesity, metabolic syndrome, chronic kidney disease, hypertension, diabetes, and diuretic use. Aboriginal and Torres Strait Islander communities have seen a dramatic rise, from essentially zero prevalence in the 1960s to 9.7% in men by 2002, mirroring the introduction of Western dietary patterns and the rise of metabolic disease.

Gout is a metabolic disease. Not a dietary indulgence. Not a lifestyle choice. A metabolic disease with genetic, environmental, dietary, and pharmacological contributors that requires clinical management, not just dietary modification.

The stages of gout nobody talks about

Most people think gout is just the acute attack. It's actually a progressive disease with distinct stages.

1. Asymptomatic hyperuricaemia. Uric acid is elevated, but there are no symptoms and no crystal deposits. This is the stage where most people could be identified but aren't, because uric acid isn't routinely tested. Progression to gout is not inevitable, but the risk increases with higher uric acid levels and longer duration of elevation.

2. Acute gout flares. Crystal deposits trigger inflammatory attacks. Between attacks, the person feels fine, but the underlying hyperuricaemia persists and crystals accumulate silently.

3. Intercritical gout. The period between attacks. It feels like remission, but it isn't. Crystal burden continues to grow, and the interval between attacks typically shortens over time without treatment.

4. Chronic tophaceous gout. Years of uncontrolled hyperuricaemia produce tophi, visible deposits of urate crystals in soft tissues around joints, in the ears, or along tendons. This stage involves chronic joint damage, erosion, and disability. It's entirely preventable with adequate urate-lowering therapy.

The tragedy is that progression through these stages is preventable. Urate-lowering therapy (primarily allopurinol in Australia) effectively reduces uric acid, dissolves crystal deposits over time, and prevents attacks and progression. But treatment requires diagnosis, and diagnosis requires testing.

Uric acid as a metabolic and cardiovascular marker

This is the section that reframes uric acid beyond gout.

Cardiovascular risk. Hyperuricaemia is a predictor of hypertension, coronary artery disease, atrial fibrillation, heart failure, stroke, and cardiovascular mortality. The mechanism may involve uric acid's pro-inflammatory, pro-oxidative, and vasoconstrictive effects on blood vessel endothelium. In the context of my dad's cardiovascular risk profile (statin for cholesterol, borderline HbA1c, family history), a uric acid hovering at the top of the range adds another data point to the metabolic picture. See the heart health article.

Metabolic syndrome. Hyperuricaemia clusters with insulin resistance, abdominal obesity, dyslipidaemia (elevated triglycerides, low HDL), and hypertension. The association is so consistent that some researchers have proposed uric acid as a component of metabolic syndrome, or at least a marker of its severity. If you've read the weight gain article and identified with the metabolic pattern, uric acid adds a dimension that standard metabolic panels miss.

Type 2 diabetes. Hyperuricaemia predicts the development of type 2 diabetes independently of other metabolic risk factors. The relationship may be mediated through fructose metabolism (which simultaneously raises uric acid and drives insulin resistance) and through uric acid's direct effects on pancreatic beta-cell function.

Uric acid is cheap to test, easy to interpret, and provides metabolic information that complements standard markers like HbA1c, lipids, and blood pressure. If you're already monitoring those markers, adding uric acid rounds out the metabolic picture.

The kidney connection

The relationship between uric acid and kidney function is bidirectional and clinically important.

Kidneys excrete uric acid. Roughly two-thirds of uric acid excretion occurs through the kidneys. When kidney function declines (reduced eGFR), uric acid excretion drops and blood levels rise. Hyperuricaemia is therefore common in chronic kidney disease, and its presence can accelerate further kidney decline.

Uric acid may damage kidneys. Animal studies and clinical data suggest that uric acid can directly damage kidney tissue through crystal deposition in the renal tubules, oxidative stress, and endothelial dysfunction. Whether treating hyperuricaemia slows CKD progression in humans is still being studied, but the association is strong enough that uric acid is monitored in most CKD patients.

Kidney stones. Elevated uric acid increases the risk of uric acid kidney stones, a distinct condition from the more common calcium oxalate stones. Uric acid stones can sometimes be dissolved by alkalinising the urine, which makes diagnosis (and distinguishing from calcium stones) important.

For kidney function context, see the kidney function article.

What drives uric acid up

Understanding the drivers helps you understand what an elevated result actually means.

Dietary purine intake. Red meat, organ meats (liver, kidney), shellfish (prawns, mussels, scallops), and certain fish (anchovies, sardines, herring). The dietary contribution is real but frequently overstated. Diet typically accounts for only about 1 mg/dL variation in uric acid levels. You can't eat your way to severe hyperuricaemia with diet alone in most cases.

Fructose. This is the underappreciated dietary driver. Fructose metabolism in the liver directly produces uric acid as a byproduct. Sugar-sweetened drinks, fruit juice in excess, and high-fructose corn syrup (less common in Australia than the US, but present in processed foods) all contribute. The rise in gout prevalence globally tracks remarkably closely with the rise in fructose consumption.

Alcohol. Beer is the worst offender (high purine content plus alcohol's effect on uric acid excretion). Spirits also raise uric acid. Wine has a more modest effect. Alcohol reduces kidney uric acid excretion and increases purine metabolism, a double hit.

Insulin resistance. Hyperinsulinaemia reduces kidney uric acid excretion. This is a major reason why hyperuricaemia clusters with metabolic syndrome: insulin resistance drives both conditions simultaneously.

Kidney dysfunction. Reduced eGFR means reduced uric acid excretion, which means elevated blood levels.

Medications. Thiazide and loop diuretics (reduce uric acid excretion), low-dose aspirin (below 1g/day reduces excretion), ciclosporin, pyrazinamide, and certain chemotherapy agents.

Cell turnover. Conditions with high cell turnover (psoriasis, myeloproliferative disorders, tumour lysis syndrome during cancer treatment) produce large amounts of purines from cell breakdown, raising uric acid.

Genetics. Uric acid levels are 40 to 70% heritable. Variants in genes encoding urate transporters (SLC2A9, ABCG2) significantly influence blood levels and gout risk. My dad's family history is a genetic clue, not just a dietary anecdote.

The Australian picture

Australia has a gout problem, and it's getting worse.

Self-reported gout prevalence ranges from 4.5% to 6.8% in Australian studies. Hyperuricaemia affects 10.5 to 16.6% of the adult population. Australia and Australasia rank among the highest-burden regions globally, alongside North America.

The global burden of gout increased by over 70% between 1990 and 2020, and is projected to continue rising through 2050. The drivers are the same metabolic forces pushing up obesity, diabetes, and cardiovascular disease: dietary changes, sedentary lifestyles, rising BMI, ageing populations, and increased use of medications that elevate uric acid.

Aboriginal and Torres Strait Islander communities have been disproportionately affected. The introduction of Western dietary patterns coincided with a dramatic rise in gout prevalence, from essentially zero in historical surveys to among the highest rates documented in any population worldwide.

And despite all this, gout remains undertreated. Studies consistently show that a minority of Australian patients with gout receive guideline-recommended urate-lowering therapy. Many are managed with acute pain relief alone, treating the flare without addressing the underlying hyperuricaemia. This is like mopping the floor without turning off the tap (to borrow a metaphor from the skin article).

How the test works

Standard blood test. Serum uric acid (also called urate) from a venous blood draw.

Fasting: Not strictly required, but fasting gives a more standardised baseline, particularly if you're also testing lipids and glucose. A high-purine meal the night before can transiently elevate uric acid.

Timing: No strong circadian variation. Morning is standard for consistency.

Preparation notes

Uric acid can be paradoxically low during an acute gout attack because the inflammatory response can temporarily reduce circulating levels. If you're in a flare, testing may underestimate your usual uric acid level. Test between attacks for the most accurate baseline.

Understanding your result

Reference ranges (approximate, varies by lab):

Men: 0.20 to 0.42 mmol/L (or 3.4 to 7.0 mg/dL)

Women (pre-menopausal): 0.15 to 0.34 mmol/L (or 2.5 to 5.7 mg/dL)

Women (post-menopausal): Ranges approach male levels as oestrogen's uricosuric effect diminishes.

Gout target: For patients with established gout, the treatment target is below 0.36 mmol/L (6.0 mg/dL), the saturation threshold below which existing crystals begin to dissolve. Some guidelines target below 0.30 mmol/L (5.0 mg/dL) for patients with tophi.

Elevated uric acid without gout symptoms: This means you have hyperuricaemia, an elevated metabolic marker that increases future risk of gout, cardiovascular events, kidney disease, and metabolic syndrome. It doesn't mean you will develop gout, but the probability increases with higher levels and longer duration.

The saturation threshold: Uric acid begins to crystallise in body fluids above approximately 0.41 mmol/L (6.8 mg/dL) at normal body temperature. This is the thermodynamic limit. Above this concentration, crystals can form, though they don't always. Crystal deposition depends on level, duration, local factors (joint temperature, pH), and individual susceptibility.

Who should be testing

Tests to consider through Bloody Good

What to do after testing

If uric acid is within range and you have no symptoms: Reassuring. No immediate action needed. If you have metabolic risk factors, consider retesting every 1 to 2 years as part of ongoing monitoring.

If uric acid is elevated but you've never had gout: This is asymptomatic hyperuricaemia. Current Australian guidelines generally don't recommend urate-lowering medication for asymptomatic hyperuricaemia alone, but the metabolic context matters. Your GP should assess your cardiovascular risk factors, kidney function, and metabolic picture. Lifestyle modification (reducing alcohol, reducing fructose and sugar-sweetened drinks, maintaining healthy weight, staying hydrated) is first-line. Some clinicians will discuss urate-lowering therapy if the level is very high (above 0.54 mmol/L / 9 mg/dL) or if multiple comorbidities are present.

If you have established gout and uric acid is above target: Discuss treatment optimisation with your GP. The target for gout patients is below 0.36 mmol/L (below 0.30 if tophi present). Allopurinol is first-line in Australia, with febuxostat as an alternative. The dose should be titrated to reach target. Many patients are on suboptimal doses. Compliance is critical: urate-lowering therapy is lifelong for most patients with recurrent gout.

If uric acid is elevated alongside declining eGFR: Kidney function and uric acid management need to be co-managed. Your GP or nephrologist will integrate both factors into the treatment plan.

Address the metabolic picture holistically. Hyperuricaemia doesn't exist in isolation. It clusters with insulin resistance, hypertension, dyslipidaemia, and obesity. Treating the metabolic environment (weight management, dietary improvement, activity, alcohol reduction) often improves uric acid alongside everything else.

Explore more biomarkers

Browse the Bloody Good Biomarker Directory